CRISPR Therapeutics AG (CRSP) Tax Provisions (2015 - 2026)

CRISPR Therapeutics AG has disclosed Tax Provisions across 12 years of filings, most recently posting $839000.0 for Q1 2026.

• Tax Provisions for Q1 2026 came in at $839000.0, down 24.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (down 24.5% YoY), and the FY2025 annual result was $3.6 million, down 10.73% from the prior year.
• Tax Provisions came in at $839000.0 for Q1 2026 at CRISPR Therapeutics AG, up from $634000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $6.1 million in Q2 2022 to a low of -$9.5 million in Q4 2022.
• The 5-year median for Tax Provisions is $900000.0 (2024), against an average of $675294.1.
• Peak annual rise in Tax Provisions reached 501.33% in 2022, while the deepest fall reached 322.77% in 2022.
• CRISPR Therapeutics AG's Tax Provisions stood at -$9.5 million in 2022, then soared by 106.9% to $657000.0 in 2023, then jumped by 80.21% to $1.2 million in 2024, then plunged by 46.45% to $634000.0 in 2025, then jumped by 32.33% to $839000.0 in 2026.
• The last three Tax Provisions figures came in at $839000.0 (Q1 2026), $634000.0 (Q4 2025), and $619000.0 (Q3 2025), per Business Quant data.